Last reviewed · How we verify
Aceclofenac and Esomeprazole
Inhibits COX-2 and blocks the action of prostaglandins, thereby reducing inflammation and pain, and also inhibits the proton pump in the stomach, thereby reducing acid production.
Inhibits COX-2 and blocks the action of prostaglandins, thereby reducing inflammation and pain, and also inhibits the proton pump in the stomach, thereby reducing acid production. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease.
At a glance
| Generic name | Aceclofenac and Esomeprazole |
|---|---|
| Also known as | Airtal and Nexium concomitant |
| Sponsor | Dong Wha Pharmaceutical Co. Ltd. |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) and proton pump inhibitor (PPI) |
| Target | COX-2 and H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 1 |
Mechanism of action
Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is responsible for the production of prostaglandins. Prostaglandins are chemical messengers that cause pain, inflammation, and fever. By inhibiting COX-2, aceclofenac reduces the production of prostaglandins, thereby reducing pain and inflammation. Esomeprazole, on the other hand, is a proton pump inhibitor (PPI) that works by blocking the action of the enzyme H+/K+ ATPase in the stomach lining, which is responsible for the production of stomach acid. By blocking this enzyme, esomeprazole reduces the production of stomach acid, thereby reducing symptoms of gastroesophageal reflux disease (GERD) and other acid-related disorders.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Dizziness
Key clinical trials
- Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aceclofenac and Esomeprazole CI brief — competitive landscape report
- Aceclofenac and Esomeprazole updates RSS · CI watch RSS
- Dong Wha Pharmaceutical Co. Ltd. portfolio CI